Takeda continued to divest a number of its over-the-counter products and other non-core assets as it attempts to rein in its Shire-related debt, the drugmaker announced Nov. 5.
What you should know:
1. Takeda reached an agreement to sell certain products to STADA Arzneimittel AG for $660 million.
2. The drug portfolio includes products sold exclusively in Russia, Georgia and several countries in the Commonwealth of Independent States.
3. This is the fourth transaction Takeda has closed in the last six months and is part of a larger effort the company has to divest $10 billion in non-core assets.
4. Takeda expects the transaction to close in the fourth quarter of fiscal year 2019.